Premium
Targeted Therapy: Dendrimer‐Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy (Adv. Therap. 2/2021)
Author(s) -
Cho Hongkwan,
Kambhampati Siva P.,
Lai Michael J.,
Zhou Lingli,
Lee Grace,
Xie Yangyiran,
Hui Qiaoyan,
Kannan Rangaramanujam M.,
Duh Elia J.
Publication year - 2021
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.202170003
Subject(s) - triamcinolone acetonide , microglia , medicine , angiogenesis , neuroinflammation , diabetic retinopathy , neuroprotection , retinal , uveitis , retina , pharmacology , cancer research , immunology , ophthalmology , inflammation , neuroscience , biology , endocrinology , diabetes mellitus
Specific and robust targeting of pathogenic cells would represent a major advance in treatment of eye diseases including diabetic retinopathy. In article number 2000181 Rangaramanujam M. Kannan, Elia J. Duh and co‐workers use the corticosteroid triamcinolone conjugated to the surface of PAMAM‐dendrimers, which are tree‐like branching polymeric nanoparticles. This dendrimer‐triamcinolone conjugate selectively targets activated, amoeboid microglia in diseased retina, reprogramming them to quiescent ramified microglia, with resulting neuroprotective effects and suppression of pathologic retinal angiogenesis. Dendrimer‐mediated drug delivery to pathogenic microglia represents a promising therapeutic strategy with high potency and low toxicity. Image credit: Sylvia Heredia